Chong Kun Dang Launches Zacubo Orally Disintegrating Tablet 15 Months After Initial Release

Expanding Treatment Options for Gastroesophageal Reflux Disease

The 37th domestically developed new drug, the P-CAB (Potassium-Competitive Acid Blocker) treatment "Zacubo Tablet," has accelerated the generational shift in the gastroesophageal reflux disease (GERD) treatment market by adding an orally disintegrating tablet (ODT) formulation just 15 months after its initial launch.

On January 6, Chong Kun Dang Pharmaceutical announced that starting from the 1st of this month, it has launched "Zacubo Orally Disintegrating Tablet 20mg" (active ingredient: Zastaprazan Citrate), a treatment for gastroesophageal reflux disease.

The newly launched "Zacubo Orally Disintegrating Tablet," which first debuted in October 2024, further strengthens the Zacubo lineup, which is already making a strong presence in the peptic ulcer agent market. Its key feature is a dramatic improvement in patient convenience.

"Zacubo Orally Disintegrating Tablet" is an ODT (Orally Disintegrating Tablet) formulation that dissolves quickly in the mouth without the need for water. It offers an optimal alternative for patients with dysphagia who have difficulty swallowing pills, as well as elderly patients who prioritize ease of administration. While the existing Zacubo Tablet is a pink, round, film-coated tablet, the new ODT formulation is a white, round tablet with a refreshing orange flavor, reducing medication aversion and improving compliance.

The "Zacubo Orally Disintegrating Tablet" maintains the key advantages of Zacubo Tablet, including rapid onset of action, long duration, and convenience of administration regardless of meals. Additionally, the new formulation offers the unique benefit of being taken without water, further enhancing the completeness of treatment.

Zacubo is scheduled to receive national health insurance coverage for the "gastric ulcer" indication, following its use for erosive gastroesophageal reflux disease. With the launch of the new ODT formulation, Zacubo has secured greater formulation diversity. At the same time, the expansion of indications is expected to create strong momentum, broadening its prescription range across the entire peptic ulcer agent market.

A Chong Kun Dang Pharmaceutical representative stated, "The launch of the orally disintegrating tablet, just 15 months after Zacubo's debut, is the result of our efforts to create a patient-friendly treatment environment. With the upcoming expansion of insurance coverage for the gastric ulcer indication, we will further elevate Zacubo's status in the peptic ulcer agent market, based on its differentiated formulation and broad indications."